Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist.
Sparks SM, Aquino C, Banker P, Collins JL, Cowan D, Diaz C, Dock ST, Hertzog DL, Liang X, Swiger ED, Yuen J, Chen G, Jayawickreme C, Moncol D, Nystrom C, Rash V, Rimele T, Roller S, Ross S. Sparks SM, et al. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1278-1283. doi: 10.1016/j.bmcl.2017.01.034. Epub 2017 Jan 17. Bioorg Med Chem Lett. 2017. PMID: 28148462
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.
Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH, Dwornik KA, Garrido DM, Golden PL, Nolte RT, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Wang L, Weiel JE. Sparks SM, et al. Bioorg Med Chem Lett. 2009 Feb 1;19(3):976-80. doi: 10.1016/j.bmcl.2008.11.085. Epub 2008 Nov 27. Bioorg Med Chem Lett. 2009. PMID: 19095442
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE. Thomson SA, et al. Among authors: sparks sm. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1177-82. doi: 10.1016/j.bmcl.2008.12.085. Epub 2008 Dec 25. Bioorg Med Chem Lett. 2009. PMID: 19138846
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
Evans KA, Shearer BG, Wisnoski DD, Shi D, Sparks SM, Sternbach DD, Winegar DA, Billin AN, Britt C, Way JM, Epperly AH, Leesnitzer LM, Merrihew RV, Xu RX, Lambert MH, Jin J. Evans KA, et al. Among authors: sparks sm. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2345-50. doi: 10.1016/j.bmcl.2011.02.077. Epub 2011 Mar 15. Bioorg Med Chem Lett. 2011. PMID: 21414782
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH, Hong JS, Hunter RN 3rd, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews CW 3rd, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK. Chan JH, et al. Among authors: sparks sm. J Med Chem. 2001 Jun 7;44(12):1866-82. doi: 10.1021/jm0004906. J Med Chem. 2001. PMID: 11384233
Glycogen phosphorylase inhibitors.
Henke BR, Sparks SM. Henke BR, et al. Among authors: sparks sm. Mini Rev Med Chem. 2006 Aug;6(8):845-57. doi: 10.2174/138955706777934991. Mini Rev Med Chem. 2006. PMID: 16918491 Review.
69 results